PARP inhibition: PARP1 and beyond

By M. Rouleau, Anand G. Patel, Michael J Hendzel, S. Kaufmann, G. Poirier. Nature Reviews. Cancer, 2010

1,292 citations recorded by the source corpus.

Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets. To provide a framework for understanding these recent observations, we review what is known about the structures and functions of the family of PARP enzymes, and then outline a series of questions that should be addressed to guide the rational development of PARP inhibitors as anticancer agents.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/04c510cfb9c8298fffad4fac0da9ed12761f5d0d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. C. Lord
2. W. Kraus
3. Alan Ashworth
4. Lisa A. Carey
5. Raga Krishnakumar
6. Xin Luo
7. L. Gianni
8. Mark J. O'Connor

In Oncology

1. W. Kraus
2. C. Lord
3. Alan Ashworth
4. Raga Krishnakumar
5. Xin Luo
6. L. Gianni
7. Mark J. O'Connor

Citations in the corpus

• SERIES: Genomic instability in cancer Balancing repair and tolerance of DNA damage caused by alkylating agents (2012, background): “Finally, chemical modulation of another DNA repair enzyme, poly(ADP-ribose) polymerase (PARP) has emerged as a potential chemotherapeutic strategy to increase cellular sensitivity to alkylating agents (reviewed in Ref”
• The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets (2010, positive): “The development of specific, potent, effective, and safe PARP inhibitors has become an area of active research and much recent excitement in the PARP field (Rouleau et al., 2010).”
• Triple-negative breast cancer: disease entity or title of convenience? (2010, background): “PARPs are critical enzymes in cell proliferation and are differentially upregulated in many cancers including TNBC and BRCA1 -associated and BRCA2 -associated tumors”
• The DNA damage response and cancer therapy (2012, background): “This modification often modulates the conformation, stability or activity of the target protei”
• On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. (2012, background): “…to a variety of other excellent reviews that cover other aspects of PARP-1 biology (D’Amours et al. 1999; Shall and de Murcia 2000; Kim et al. 2005; Gagne et al. 2006; Schreiber et al. 2006; Hassa and Hottiger 2008; Kraus 2008; Ji and Tulin 2010; Krishnakumar and Kraus 2010a; Rouleau et al. 2010).”